{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-23-000087","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.686613+00:00","generated_at":"2026-06-12T05:16:49.599808+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Axogen Q2 revenue $38.2M (+11% YoY); net loss narrows to $6.7M","bullets":["Revenue $38.2M in Q2 2023, up 11% vs Q2 2022; scheduled procedures grew >20%, trauma low-single-digit.","Net loss $6.7M ($0.16 per share) vs $7.7M loss a year ago; adjusted net loss $1.3M ($0.03 per share).","Gross margin 81.1% (vs 81.8% YoY); cash & investments $40.8M; $3.6M capex for new Dayton processing facility.","FY 2023 revenue guidance maintained at $154M-$159M (11-15% growth); gross margin expected ~80% for full year.","Pilot launched Axoguard HA+ Nerve Protector; BLA submission for Avance expected Q1-Q2 2024 with target approval H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-23-000087","json":"https://secwatch.observer/filing/0000805928-23-000087.json","markdown":"https://secwatch.observer/filing/0000805928-23-000087.md","text":"https://secwatch.observer/filing/0000805928-23-000087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000087/0000805928-23-000087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000087/axgn-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T05:16:49.599808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d9593a80b1d0b2f9341f424c567e04850daa7728","claim":"Axogen, Inc. updated its six months ended June 30, 2023 guidance (reaffirmed).","evidence_excerpt":"On July 26, 2023, Axogen, Inc. (the “Company”) issued a press release announcing its three and six months ended June 30, 2023 financial results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000087/0000805928-23-000087-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"six months ended June 30, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ec29a880c4e104d57f0e8ab88c5adc4c18bb40f3","claim":"Axogen, Inc. reported second quarter ended June 30, 2023 results: revenue $38.2 million, net income $6.7 million, EPS $0.16 per share. Guidance reaffirmed.","evidence_excerpt":"today reported financial results and business highlights for the second quarter ended June 30, 2023. Second Quarter Financial Results and Business Highlights • Revenue was $38.2 million during the second quarter, an increase of approximately 11% over the second quarter of 2022. • The Company estimates that revenues from scheduled non-trauma procedures","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000087/0000805928-23-000087-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$38.2 million"},{"label":"Net income","value":"$6.7 million"},{"label":"EPS","value":"$0.16 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}